Spatial organization of CAF subtypes establishes a VCAN‑laden neurogenesis‑mimicry barrier driving immune exclusion and immunotherapy resistance in gastric cancer
This study identifies a spatially organized fibroblast-driven neurogenesis mimicry program in gastric cancer, centered on VCAN-rich extracellular matrix deposition, which physically traps T cells and activates pro-tumor signaling to establish an immune-excluded barrier that drives immunotherapy resistance.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Cancer is not merely a collection of rogue cells growing out of control; it is a complex ecosystem where the tumor and its surrounding neighborhood interact constantly. In the stomach, as in other organs, a tumor does not exist in a vacuum. It is embedded in a landscape of connective tissue and immune cells known as the tumor microenvironment. For years, doctors have hoped that immunotherapy, a treatment that wakes up the body's own immune system to fight cancer, would work for everyone. Yet, in many patients, the treatment fails. The immune cells simply cannot reach the tumor. They are blocked by a dense, fibrous wall that the tumor builds around itself, a phenomenon scientists call "immune exclusion." Understanding how this wall is built, and who builds it, is the key to unlocking better treatments for stomach cancer.
A team of researchers at Harbin Medical University has now mapped the construction of this barrier with unprecedented detail. They discovered that the wall is not just random scar tissue, but a highly organized structure built by specific types of support cells called fibroblasts. These cells, which normally help heal wounds, have been hijacked by the cancer. Instead of just forming a barrier, they have reprogrammed themselves to mimic the behavior of nerve cells, a strange process the researchers call "neurogenesis mimicry." This mimicry creates a double threat: it forms a physical fortress that traps immune soldiers outside the tumor, and it sends chemical signals that trick the cancer cells into becoming more aggressive and invasive.
To uncover this hidden architecture, the scientists analyzed tissue samples from hundreds of patients, combining data from thousands of individual cells with high-resolution maps of how those cells are arranged in space. They found that not all support cells are the same. Within the tumor, a specific trio of fibroblast subtypes takes charge. These cells are marked by specific proteins and are driven by a powerful internal signal known as the Wnt pathway. When these fibroblasts activate, they begin to produce a massive amount of a protein called VCAN. This protein acts like a molecular glue, weaving a dense, stiff mesh around the tumor.
The researchers showed that this VCAN-rich mesh does two dangerous things. First, it acts as a physical wall. Using advanced imaging and 3D models, they watched immune cells, specifically the CD8 T cells designed to kill cancer, try to enter the tumor. In the presence of this dense mesh, the immune cells became stuck in the outer layers, unable to penetrate the core where the cancer cells hide. The wall effectively excludes the very cells needed to cure the disease. Second, the VCAN protein is not just a passive barrier; it is an active signal. When it touches the surface of cancer cells, it binds to a receptor called Integrin beta-1. This binding triggers a chain reaction inside the cancer cell, turning on pathways that make the cell behave more like a nerve cell. This transformation makes the cancer more mobile, more resistant to treatment, and more likely to spread.
The study ruled out the idea that this neural-like behavior comes from actual nerves growing into the tumor. Instead, the evidence points clearly to the fibroblasts themselves as the source. By using computer models to simulate the removal of specific genes, the team confirmed that if they stopped these fibroblasts from producing VCAN, the physical barrier collapsed, and the cancer cells lost their nerve-like traits. In experiments using mice, when the researchers combined standard immunotherapy with a strategy to remove this VCAN barrier, the immune system was finally able to reach the tumor, leading to significant tumor shrinkage and improved survival.
This work changes the way we view the failure of immunotherapy in stomach cancer. It suggests that the problem is not just the cancer cells themselves, but the specific support cells that build an impermeable fortress around them. The researchers identified a set of genes that can predict which patients are likely to have this high-risk, immune-excluded tumor type. By targeting the VCAN protein or the fibroblasts that produce it, doctors may be able to break down the wall, allowing the immune system to do its job. The findings offer a clear path forward: to treat the cancer, we must first dismantle the protective shell the tumor has built for itself.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.